PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Triple Negative Breast Cancer
Age: Between 18 - 100 Years
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required